Equities research analysts at Wedbush assumed coverage on shares of Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) in a research report issued on Thursday, Marketbeat.com reports. The brokerage set an "outperform" rating and a $31.00 price target on the stock. Wedbush's target price would indicate a potential upside of 155.56% from the company's current price.
BCAX has been the subject of several other reports. HC Wainwright increased their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a "strong-buy" rating in a report on Tuesday, November 5th. Finally, Rodman & Renshaw started coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating and a $48.00 price target for the company. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $41.20.
Get Our Latest Stock Report on BCAX
Bicara Therapeutics Stock Performance
Shares of Bicara Therapeutics stock traded down $0.47 during trading on Thursday, hitting $12.13. 253,436 shares of the company's stock traded hands, compared to its average volume of 352,690. The business's fifty day simple moving average is $15.66. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). On average, equities analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Bicara Therapeutics
Large investors have recently modified their holdings of the stock. Spire Wealth Management bought a new stake in Bicara Therapeutics during the 4th quarter worth about $31,000. SG Americas Securities LLC acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $147,000. Cinctive Capital Management LP bought a new stake in shares of Bicara Therapeutics during the third quarter worth approximately $229,000. Barclays PLC acquired a new position in Bicara Therapeutics in the third quarter valued at approximately $255,000. Finally, Jane Street Group LLC bought a new position in Bicara Therapeutics in the third quarter valued at approximately $309,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
